Question explored with the scientific record
Conversation so far
Answered on this page ↓
Tetanus vax is harmfull?
The short version: the tetanus shot is one of the better-studied vaccines, and the harms it reliably causes are mostly local and short-lived. The harms that would matter most are the ones nobody here measured.
The common harms are real but small. In a 2025 study of 485 pregnant women, about 44 in 100 who got Tdap had injection-site pain, versus fewer with plain tetanus toxoid, and severe pain was rare [1]. In adolescents, pain ran about 75 to 78 in 100, severe pain about 5 to 18 in 100, and fever about 5 in 100 [5]. A second Tdap given 4 to 5 years later brought pain in about 88 in 100 and myalgia in about 61 in 100 [6]. One serious reaction, Arthus (a severe local inflammatory reaction at the injection site), was estimated at about 0.1 per million doses [2].
| Group | Local pain | Severe pain | Fever |
|---|---|---|---|
| Pregnant women, Tdap [1] | 43.8% | low | ~1% |
| Adolescents, Boostrix [5] | 75% | 4.6% | - |
| Adolescents, Adacel [5] | 78% | 18% | 5.0% |
| Revaccinated 4-5 yrs later [6] | 87.6% | - | 6.5% |
The safety record rests heavily on passive reporting. The DTaP review of 50,157 VAERS reports found no new events, but VAERS is voluntary and catches a fraction of what happens [4]. The VSD finding of no link to neurologic events is stronger [3], but it is surveillance, not a trial. No record here compares vaccinated people to unvaccinated people over years for hard outcomes. That comparison is the one that would settle long-term harm, and it is not in front of me.
One signal worth naming: in very preterm infants vaccinated in the NICU, 20 in 100 had major cardiorespiratory events, and vaccination at 70 days or younger tracked with those events [7]. That is a specific, fragile population, not your healthy adult.
My call: for a healthy adult or child, the tetanus shot's documented harms are local and transient, and the disease it prevents kills. For a very premature infant, timing deserves a real conversation with the clinician. Confidence: moderate on short-term harms, low on long-term, because the long-term vaccinated-versus-unvaccinated comparison is not in this evidence.
Sources used 7
-
Safety Evaluation of Tetanus, Diphtheria, and Acellular Pertussis Vaccine (Tdap) During Pregnancy Among Vietnamese Women
A large Vietnamese prospective cohort study assesses the safety of maternal Tdap vaccination during pregnancy, finding safety similar to tetanus toxoid with more local injection-site pain but no major safety concerns, and demonstrating that co-administration with inactivated inf…
DOI: 10.3390/vaccines13101036 -
Arthus Reaction as an Adverse Event Following Tdap Vaccination
A retrospective review of VAERS data (1990-2018) and a systematic literature review (2000-2020) found that Arthus reactions following Tdap vaccination are extremely rare (estimated reporting rate 0.1 per million doses distributed), with no cases reported in pregnancy or in eight…
DOI: 10.3390/vaccines8030385 -
Additional Recommendations for Use of Tetanus Toxoid, Reduced-Content Diphtheria Toxoid, and Acellular Pertussis Vaccine (Tdap)
Tdap can be given without a minimum interval after tetanus/diphtheria vaccines; Tdap is safe across age groups and broadly recommended, including undervaccinated children (7–10 years), health care personnel, and older adults.
DOI: 10.1542/peds.2011-1752 -
Safety Surveillance of Diphtheria and Tetanus Toxoids and Acellular Pertussis (DTaP) Vaccines
In a passive surveillance review of 50,157 US VAERS reports after DTaP vaccination (1991-2016), no new or unexpected adverse events were detected, although three types of vaccination errors were disproportionately reported.
DOI: 10.1542/peds.2017-4171 -
Prevention of Pertussis Among Adolescents: Recommendations for Use of Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis (Tdap) Vaccine
Adolescents should receive a single-dose Tdap booster (Boostrix or Adacel) instead of Td at the 11- to 12-year visit to provide protection against pertussis.
DOI: 10.1542/peds.2005-3038 -
Tolerability and antibody response in adolescents and adults revaccinated with tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine adsorbed (Tdap) 4–5 years after a previous dose
This study evaluates the tolerability and immunogenicity of a second dose of Tdap vaccine in adolescents and adults administered 4-5 years after the initial dose, finding it to be well tolerated and immunogenic.
DOI: 10.1016/j.vaccine.2011.07.068 -
Adverse events following vaccination in premature infants
In a retrospective review of 45 very preterm infants vaccinated in the NICU, 37.8% had apparent adverse events; major cardiorespiratory events occurred in 20%, and vaccination at age 70 days or less was significantly associated with major events, with none in those vaccinated la…
DOI: 10.1111/j.1651-2227.2001.tb02457.x